Bird steps into the role with a background spanning leadership positions at Orion Pharma, Medreich, and Meda, alongside earlier tenures at Johnson & Johnson and Sanofi-Aventis. His mandate focuses on broadening the company’s reach into New Zealand, Asia, and Northern Europe, while maintaining the supply of high-potency and multi-format vial medications manufactured in Western Australia.
LumaCina Appoints Industry Veteran Gary Bird as CEO
Gary Bird has been named Chief Executive Officer of LumaCina, a Perth-based pharmaceutical supplier, as the company pivots toward international expansion. The appointment aims to leverage Bird’s three decades of experience in the Australian pharmaceutical sector to scale the firm’s sterile injectables portfolio across global hospital markets.
Executive Chair Mark Crotty, who initiated the search for a new CEO, will retain his post to oversee long-term strategic development and platform growth. According to Dr. Masood Tayebi, co-founder of parent firm Bridgewest Group, this dual-leadership structure is intended to blend continuity with aggressive commercial execution. Bird has already begun integrating with the leadership team, signaling a transition from the company’s foundational phase toward a more resilient, globally-oriented pharmaceutical enterprise.
Comments (0)
No comments yet. Be the first!